Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers in HER2+ MBC treated with Trastuzumab + Lapatinib or Chemotherapy
NCT02213042Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2014
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of lapatinib in HER2-positive metastatic breast cancer (3 arms), sponsored by Novartis. Primary endpoint: Fold Change in Expression Profile of Genes and/or Proteins. Started Oct 2014; status: terminated.
02
Drugs
lapatinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT02213042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213042.